The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy.
A. Gerger
No relevant relationships to disclose
W. Zhang
No relevant relationships to disclose
D. Yang
No relevant relationships to disclose
P. O. Bohanes
No relevant relationships to disclose
Y. Ning
No relevant relationships to disclose
T. Winder
No relevant relationships to disclose
M. J. Labonte
No relevant relationships to disclose
P. M. Wilson
No relevant relationships to disclose
L. Benhaim
No relevant relationships to disclose
R. El-Khoueiry
No relevant relationships to disclose
G. Absenger
No relevant relationships to disclose
A. B. El-Khoueiry
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
S. Iqbal
Honoraria - Roche/Genentech
H. Lenz
Consultant or Advisory Role - Roche/Genentech